Covered recipient · General Payments record
ESTELAMARI RODRIGUEZ
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$51,015.99
120 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $45,546.75 | 17 |
| Food and Beverage | $3,471.45 | 96 |
| Travel and Lodging | $1,980.02 | 6 |
| Education | $17.77 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Biotech, Inc. | $34,397.34 | 25 |
| AstraZeneca Pharmaceuticals LP | $7,411.27 | 20 |
| Amgen Inc. | $4,116.00 | 1 |
| PFIZER INC. | $1,639.40 | 6 |
| Daiichi Sankyo Inc. | $1,283.38 | 9 |
| Merck Sharp & Dohme LLC | $296.52 | 10 |
| Caris MPI, Inc. | $253.61 | 6 |
| Regeneron Healthcare Solutions, Inc. | $251.07 | 4 |
| Genentech, Inc. | $152.64 | 1 |
| Gilead Sciences, Inc. | $148.57 | 3 |
| Janssen Global Services, LLC | $145.20 | 1 |
| Janssen Scientific Affairs, LLC | $137.57 | 1 |
| AstraZeneca UK Limited | $134.58 | 1 |
| Lilly USA, LLC | $128.69 | 7 |
| E.R. Squibb & Sons, L.L.C. | $116.82 | 6 |
| ARRAY BIOPHARMA INC | $89.87 | 6 |
| Novartis Pharmaceuticals Corporation | $78.90 | 3 |
| Genentech USA, Inc. | $52.86 | 2 |
| JAZZ PHARMACEUTICALS INC. | $43.81 | 2 |
| Stemline Therapeutics Inc. | $43.78 | 2 |
| Immunocore Limited | $35.48 | 1 |
| Novocure Inc. | $22.10 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $19.70 | 1 |
| Eisai Inc. | $16.83 | 1 |
Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ESTELAMARI RODRIGUEZ
NPI 1194887034 · CMS profile ID 144552
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
MIAMI, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1194887034?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ESTELAMARI RODRIGUEZ, NPI 1194887034, CMS profile ID 144552. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194887034?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). ESTELAMARI RODRIGUEZ, NPI 1194887034, CMS profile ID 144552. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194887034?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- ESTELAMARI RODRIGUEZ, NPI 1194887034, CMS profile ID 144552, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1194887034?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
120 matching records · $51,015.99 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 120.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Immunocore Limited | $35.48 | 06/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1235825562 | CMS |
| AstraZeneca Pharmaceuticals LP | $76.00 | 06/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1215325974 | CMS |
| Merck Sharp & Dohme LLC | $113.63 | 05/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238223574 | CMS |
| Janssen Biotech, Inc. | $3,906.25 | 05/27/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175141217 | CMS |
| Janssen Biotech, Inc. | $20.35 | 05/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175137679 | CMS |
| Janssen Biotech, Inc. | $0.77 | 05/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175154129 | CMS |
| Caris MPI, Inc. | $76.33 | 05/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234285590 | CMS |
| Caris MPI, Inc. | $61.79 | 05/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234285593 | CMS |
| E.R. Squibb & Sons, L.L.C. | $32.85 | 05/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184460485 | CMS |
| Merck Sharp & Dohme LLC | $19.35 | 05/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238047389 | CMS |
| Merck Sharp & Dohme LLC | $19.55 | 05/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238092083 | CMS |
| Novocure Inc. | $22.10 | 05/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1251145989 | CMS |
| Merck Sharp & Dohme LLC | $16.69 | 05/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238141996 | CMS |
| Janssen Biotech, Inc. | $20.00 | 05/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175136563 | CMS |
| Janssen Biotech, Inc. | $40.00 | 05/10/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175155080 | CMS |
| Janssen Biotech, Inc. | $43.16 | 05/10/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175155167 | CMS |
| Janssen Biotech, Inc. | $390.73 | 05/10/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175156050 | CMS |
| Daiichi Sankyo Inc. | $29.41 | 05/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197061635 | CMS |
| Daiichi Sankyo Inc. | $0.91 | 05/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197068707 | CMS |
| Janssen Biotech, Inc. | $114.05 | 05/09/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175138167 | CMS |
| Janssen Biotech, Inc. | $396.47 | 05/09/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175153290 | CMS |
| Lilly USA, LLC | $21.10 | 05/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186581516 | CMS |
| Lilly USA, LLC | $13.98 | 05/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186639511 | CMS |
| AstraZeneca Pharmaceuticals LP | $32.01 | 05/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1215335722 | CMS |
| AstraZeneca Pharmaceuticals LP | $26.94 | 05/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1214800379 | CMS |
| Daiichi Sankyo Inc. | $14.01 | 04/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197066531 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.16 | 04/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1215348172 | CMS |
| Lilly USA, LLC | $17.19 | 04/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186581518 | CMS |
| Gilead Sciences, Inc. | $26.29 | 04/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234463759 | CMS |
| Janssen Biotech, Inc. | $1,250.00 | 04/18/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175158293 | CMS |
| ARRAY BIOPHARMA INC | $5.77 | 04/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229570998 | CMS |
| JAZZ PHARMACEUTICALS INC. | $22.42 | 04/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234333319 | CMS |
| Novartis Pharmaceuticals Corporation | $17.12 | 04/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200567925 | CMS |
| Janssen Biotech, Inc. | $124.82 | 04/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175144083 | CMS |
| ARRAY BIOPHARMA INC | $1.13 | 04/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229468973 | CMS |
| ARRAY BIOPHARMA INC | $25.21 | 04/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1229497596 | CMS |
| Lilly USA, LLC | $17.65 | 04/01/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1186581514 | CMS |
| Janssen Biotech, Inc. | $4,687.50 | 03/31/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175139677 | CMS |
| Janssen Biotech, Inc. | $22.63 | 03/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175148112 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.45 | 03/17/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1215338483 | CMS |
| Daiichi Sankyo Inc. | $27.81 | 03/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197053009 | CMS |
| Janssen Biotech, Inc. | $33.69 | 03/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175138262 | CMS |
| E.R. Squibb & Sons, L.L.C. | $20.64 | 03/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1184460477 | CMS |
| Janssen Biotech, Inc. | $42.93 | 03/04/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175138275 | CMS |
| Janssen Biotech, Inc. | $789.73 | 03/04/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175152801 | CMS |
| Janssen Biotech, Inc. | $245.88 | 03/04/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1175156085 | CMS |
| Daiichi Sankyo Inc. | $26.98 | 03/03/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197045749 | CMS |
| Novartis Pharmaceuticals Corporation | $31.25 | 02/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1200567921 | CMS |
| AstraZeneca UK Limited | $134.58 | 02/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211400746 | CMS |
| Gilead Sciences, Inc. | $22.49 | 02/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234499943 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $435,281.05 | 47 |
| PY2024 | Principal investigator | $249,478.57 | 11 |
| PY2023 | Recipient | $3,200.00 | 1 |
| PY2023 | Principal investigator | $151,780.41 | 4 |
| PY2022 | Principal investigator | $86,717.05 | 5 |
| PY2020 | Principal investigator | $3,658.16 | 2 |
| PY2019 | Principal investigator | $51,696.01 | 14 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
47 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $35,559.63 | 12/31/2025 | Non-covered Recipient Entity University of Miami Sylvester Comprehensive Cancer Center - Aventura | An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than | No dispute reported | 06/30/2026 | 1232928916 |
| Principal investigator 1 | Janssen Research & Development, LLC | $22,070.00 | 12/29/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175391171 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $952.00 | 12/26/2025 | Non-covered Recipient Entity University Of Miami | Phase 1b Single Arm, Open-label Trial of RYZ101 in Combination With Carboplatin + Etoposide + Atezolizumab in Subjects With Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC) | No dispute reported | 06/30/2026 | 1235992485 |
| Principal investigator 1 | Genentech, Inc. | $4,531.00 | 12/18/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI OFFICE OF RESEARCH ADMINISTRATION | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS | No dispute reported | 06/30/2026 | 1211678698 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $976.00 | 12/15/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI | DS7300-188 | No dispute reported | 06/30/2026 | 1223386630 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,124.00 | 12/15/2025 | Non-covered Recipient Entity University Of Miami | DS7300-188 | No dispute reported | 06/30/2026 | 1225318420 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 12/08/2025 | Non-covered Recipient Entity University Miami Miller School Of Medicine | DS7300-188 | No dispute reported | 06/30/2026 | 1223386267 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 12/08/2025 | Non-covered Recipient Entity University Miami Miller School Of Medicine | DS7300-188 | No dispute reported | 06/30/2026 | 1223386269 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $18.25 | 12/08/2025 | Non-covered Recipient Entity University Miami Miller School Of Medicine | DS7300-188 | No dispute reported | 06/30/2026 | 1223386271 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $11.55 | 12/08/2025 | Non-covered Recipient Entity University Miami Miller School Of Medicine | DS7300-188 | No dispute reported | 06/30/2026 | 1223386273 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $20.85 | 12/08/2025 | Non-covered Recipient Entity University Miami Miller School Of Medicine | DS7300-188 | No dispute reported | 06/30/2026 | 1223386275 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,560.00 | 11/19/2025 | Non-covered Recipient Entity University Of Miami | DS7300-188 | No dispute reported | 06/30/2026 | 1225318414 |
| Principal investigator 1 | Genentech, Inc. | $4,531.00 | 11/18/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI OFFICE OF RESEARCH ADMINISTRATION | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS | No dispute reported | 06/30/2026 | 1211678696 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,506.00 | 11/03/2025 | Non-covered Recipient Entity University Of Miami | DS7300-188 | No dispute reported | 06/30/2026 | 1225318408 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6,374.00 | 11/03/2025 | Non-covered Recipient Entity University Of Miami | DS7300-188 | No dispute reported | 06/30/2026 | 1225318412 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,124.00 | 11/03/2025 | Non-covered Recipient Entity University Of Miami | DS7300-188 | No dispute reported | 06/30/2026 | 1225318422 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,406.00 | 11/03/2025 | Non-covered Recipient Entity University Of Miami | DS7300-188 | No dispute reported | 06/30/2026 | 1225318424 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 11/03/2025 | Non-covered Recipient Entity University Of Miami | DS7300-188 | No dispute reported | 06/30/2026 | 1225318426 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,124.00 | 11/03/2025 | Non-covered Recipient Entity University Of Miami | DS7300-188 | No dispute reported | 06/30/2026 | 1225318428 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,219.00 | 11/03/2025 | Non-covered Recipient Entity University Of Miami | DS7300-188 | No dispute reported | 06/30/2026 | 1225318430 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $200.00 | 11/03/2025 | Non-covered Recipient Entity University Of Miami | DS7300-188 | No dispute reported | 06/30/2026 | 1225318436 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 10/17/2025 | Non-covered Recipient Entity University Of Miami | DS7300-188 | No dispute reported | 06/30/2026 | 1225318410 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,500.00 | 10/17/2025 | Non-covered Recipient Entity University Of Miami | DS7300-188 | No dispute reported | 06/30/2026 | 1225318416 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $205.00 | 10/17/2025 | Non-covered Recipient Entity University Of Miami | DS7300-188 | No dispute reported | 06/30/2026 | 1225318418 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,515.00 | 10/17/2025 | Non-covered Recipient Entity University Of Miami | DS7300-188 | No dispute reported | 06/30/2026 | 1225318432 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,440.00 | 10/17/2025 | Non-covered Recipient Entity University Of Miami | DS7300-188 | No dispute reported | 06/30/2026 | 1225318434 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,519.36 | 10/17/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MIAMI HOSPITAL | AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION, PHASE 1A/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-500, A NOVEL STIMULATOR OF INTERFERON GENES AGONIST, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272461 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 10/13/2025 | Non-covered Recipient Entity University Miami Miller School Of Medicine | DS7300-188 | No dispute reported | 06/30/2026 | 1223386257 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 10/13/2025 | Non-covered Recipient Entity University Miami Miller School Of Medicine | DS7300-188 | No dispute reported | 06/30/2026 | 1223386259 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 10/13/2025 | Non-covered Recipient Entity University Miami Miller School Of Medicine | DS7300-188 | No dispute reported | 06/30/2026 | 1223386261 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 10/13/2025 | Non-covered Recipient Entity University Miami Miller School Of Medicine | DS7300-188 | No dispute reported | 06/30/2026 | 1223386263 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 10/13/2025 | Non-covered Recipient Entity University Miami Miller School Of Medicine | DS7300-188 | No dispute reported | 06/30/2026 | 1223386265 |
| Principal investigator 1 | Genentech, Inc. | $9,900.00 | 10/09/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI OFFICE OF RESEARCH ADMINISTRATION | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS | No dispute reported | 06/30/2026 | 1211678692 |
| Principal investigator 1 | Genentech, Inc. | $40,220.00 | 10/09/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI OFFICE OF RESEARCH ADMINISTRATION | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS | No dispute reported | 06/30/2026 | 1211678694 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $27,025.00 | 09/30/2025 | Non-covered Recipient Entity University Of Miami | A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% | No dispute reported | 06/30/2026 | 1235992483 |
| Principal investigator 1 | Genentech, Inc. | $25,039.00 | 08/22/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI OFFICE OF RESEARCH ADMINISTRATION | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS | No dispute reported | 06/30/2026 | 1211678686 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $93,521.76 | 08/22/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MIAMI HOSPITAL | AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION, PHASE 1A/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-500, A NOVEL STIMULATOR OF INTERFERON GENES AGONIST, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272447 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,284.07 | 07/09/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MIAMI HOSPITAL | AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION, PHASE 1A/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-500, A NOVEL STIMULATOR OF INTERFERON GENES AGONIST, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272423 |
| Principal investigator 1 | Genentech, Inc. | $26,628.00 | 06/10/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI OFFICE OF RESEARCH ADMINISTRATION | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS | No dispute reported | 06/30/2026 | 1211678676 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $14,953.20 | 05/28/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE | AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION, PHASE 1A/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-500, A NOVEL STIMULATOR OF INTERFERON GENES AGONIST, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223280396 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $680.00 | 05/28/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE | AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION, PHASE 1A/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-500, A NOVEL STIMULATOR OF INTERFERON GENES AGONIST, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223280398 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $988.48 | 05/28/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE | AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION, PHASE 1A/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-500, A NOVEL STIMULATOR OF INTERFERON GENES AGONIST, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223280400 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,040.00 | 05/28/2025 | Non-covered Recipient Entity UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE | AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION, PHASE 1A/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-500, A NOVEL STIMULATOR OF INTERFERON GENES AGONIST, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223280402 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,096.06 | 04/23/2025 | Covered Recipient Teaching Hospital University Of Miami Hospital | A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% | No dispute reported | 06/30/2026 | 1235999760 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $16,418.00 | 02/24/2025 | Non-covered Recipient Entity University of Miami Hospital and Clinics, Sylvester Cancer Center | An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than | No dispute reported | 06/30/2026 | 1232928914 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $28,420.70 | 02/05/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MIAMI HOSPITAL | AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION, PHASE 1A/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-500, A NOVEL STIMULATOR OF INTERFERON GENES AGONIST, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272275 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,240.64 | 01/03/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF MIAMI HOSPITAL | AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION, PHASE 1A/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-500, A NOVEL STIMULATOR OF INTERFERON GENES AGONIST, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1223272257 |